add directory ♦ physician employment
Today's News:
Yahoo! News Search Results for Cardiovascular Disorders
QuatRx Completes Patient Enrollment In Phase 3 Study Of Ophena(TM) In Women With Postmenopausal Vaginal Syndrome (Medical News Today)
Thu, 23 Aug 2007 08:13:10 GMT
QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemife [click link for full article]
Data on PolyMedix Antimicrobial Polymers Being Presented at Annual Meeting of the American Chemical Society (Business Wire via Yahoo! Finance)
Wed, 22 Aug 2007 14:42:00 GMT
PHILADELPHIA----PolyMedix, Inc. , an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced that Dr.
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome (PR Newswire via Yahoo! Finance)
Wed, 22 Aug 2007 11:00:00 GMT
QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena , the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with ...
Medicure Reports Highlights and Financial Results for Fiscal 2007 (Marketwire via Yahoo! Finance)
Thu, 23 Aug 2007 12:00:00 GMT
Medicure Inc.(AMEX: MCU), a cardiovascular focused, biopharmaceutical company, today reported the results of operations for the fiscal year ended May 31, 2007. All amounts referenced herein are in Canadian dollars unless otherwise noted.
Medicure to Report Fiscal 2007 Results on August 23, 2007 (Marketwire via Yahoo! Finance)
Wed, 22 Aug 2007 20:19:00 GMT
Medicure Inc.(AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced that the Company will report financial results for fiscal 2007 on Thursday, August 23, 2007 at 8:00 AM Eastern Time.
Lexicon Presents Class Of Compounds Modulating TPH1, The Target For Its LX1031 Investigational Drug For Irritable Bowel ... (Medical News Today)
Wed, 22 Aug 2007 08:15:30 GMT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by the company as potential treatments for irritable bowel syndrome (IBS) and other gastrointestinal disorders. [click link for full article]
Subscribe to Cardiovascular_Disorders RSS feed 
QuatRx Completes Patient Enrollment In Phase 3 Study Of Ophena(TM) In Women With Postmenopausal Vaginal Syndrome (Medical News Today)
Thu, 23 Aug 2007 08:13:10 GMT
QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemife [click link for full article]
Data on PolyMedix Antimicrobial Polymers Being Presented at Annual Meeting of the American Chemical Society (Business Wire via Yahoo! Finance)
Wed, 22 Aug 2007 14:42:00 GMT
PHILADELPHIA----PolyMedix, Inc. , an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced that Dr.
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome (PR Newswire via Yahoo! Finance)
Wed, 22 Aug 2007 11:00:00 GMT
QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena , the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with ...
Medicure Reports Highlights and Financial Results for Fiscal 2007 (Marketwire via Yahoo! Finance)
Thu, 23 Aug 2007 12:00:00 GMT
Medicure Inc.(AMEX: MCU), a cardiovascular focused, biopharmaceutical company, today reported the results of operations for the fiscal year ended May 31, 2007. All amounts referenced herein are in Canadian dollars unless otherwise noted.
Medicure to Report Fiscal 2007 Results on August 23, 2007 (Marketwire via Yahoo! Finance)
Wed, 22 Aug 2007 20:19:00 GMT
Medicure Inc.(AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced that the Company will report financial results for fiscal 2007 on Thursday, August 23, 2007 at 8:00 AM Eastern Time.
Lexicon Presents Class Of Compounds Modulating TPH1, The Target For Its LX1031 Investigational Drug For Irritable Bowel ... (Medical News Today)
Wed, 22 Aug 2007 08:15:30 GMT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by the company as potential treatments for irritable bowel syndrome (IBS) and other gastrointestinal disorders. [click link for full article]
Sites:
Health.iafrica.com: health and fitness includes a doctor online, dietician online, psychologist online, fitness expert and parenting adviceUniversity of Michigan Cardiovascular Center: Information for patients and families concerning congenital diseases, surgery, and preventive programs.
This directory is based on the Open Directory and may have been modified